Participated · Seed · Jul 2026

Mätch VC is building a research-backed, reasoning-first causal world model intended to learn from minimal data and adapt to situations it has not seen before. The company frames its mission as creating world-class AI "Made in Europe" and emphasizes a science-first approach. It announced a €12M seed round to support the next phase of development and to advance its research and team. The company named a broad set of research collaborators and angels in its announcement, indicating close ties to academic and industry experts. No revenue, user metrics, founding year, or valuation were disclosed in the announcement.

Participated · Seed · Jul 2026

kausable AI builds reasoning-first foundation models that learn causal relationships from synthetic data to adapt quickly to new situations using only a handful of examples. The startup's core product is a causal "world model" architecture and associated models like TipPFN, a zero-shot forecasting model that predicts tipping points across domains such as medicine and energy. Founded by Johannes Haux (CEO), Dr Benjamin Herdeanu (CTO) and Gregor Ramien (COO) in 2025 out of research at Heidelberg University, the company has a nine-person team and has published research including a paper co-authored with Columbia University collaborators. Financially, kausable raised roughly €1.5M in pre-seed financing and has now secured €12M in a seed round led by UVC Partners and Entourage, supplemented by strategic angel backers. Over the next year it intends to expand the team, run customer pilot projects, become more product-focused, and target applications in robotics, healthcare, forecasting and industrial systems.

Participated · Equity · Jun 2026

Spot Biosystems is developing an engineered extracellular vesicle (EV) delivery platform designed to encapsulate large nucleic acid cargo and enable repeat, non-viral dosing to skeletal muscle. The company reported a peer-reviewed study in Nature Biomedical Engineering showing EV-delivered full-length dystrophin mRNA produced sustained protein expression and improved muscle function in DMD knockout mice and sustained expression without organ toxicity in non-human primates. Spot has launched an investigator-initiated first-in-human trial at Shanghai Children's Medical Center, where the first two pediatric patients demonstrated respective 1000%+ and 2000%+ increases in dystrophin after one month and functional improvement lasting up to six months after dosing cessation. The platform is positioned to overcome limitations of AAV-based approaches by supporting larger cargo and repeat dosing. Financially, Spot emerged from stealth with $40 million in venture financing from a syndicate including LDV Partners, IDG Capital, Advantech Capital, Tiger Jade Capital, Shanda Ventures, the Stanford StartX fund, and Saltagen Ventures. The company intends to use clinical data from the IIT to inform future regulatory pathways and further clinical development for Duchenne muscular dystrophy.

Participated · Seed · May 2026

RadixArk is a spin-out from UC Berkeley that maintains SGLang, an open-source engine designed to make the inference phase of large language models markedly faster and cheaper. The platform is already in use by teams at xAI and Cursor to boost training and real-time inference performance. Building on this foundation, RadixArk will keep SGLang free while offering paid cloud hosting and releasing new products such as Miles, a reinforcement-learning framework that helps models improve over time. The effort began in 2023 under Databricks co-founder Ion Stoica and has now transitioned into an independent commercial entity. Although much of its software remains open source, the company has introduced revenue-generating hosting services to capitalize on enterprise demand for AI infrastructure. RadixArk’s latest fundraising values the firm at roughly $400 million, giving it resources to expand product development and go-to-market efforts.

Participated · Series C · Jan 2026

Founded in 2018, Fiddler AI has built an all-in-one observability and security platform that serves as a control plane for compound AI systems, giving enterprises standardized telemetry, evaluation, continuous monitoring, policy enforcement, and auditable governance. The product includes proprietary Trust Models that provide out-of-the-box accuracy, safety, and compliance checks, enabling Fortune 500 customers to diagnose, explain, and manage AI agent behavior in real time. Over the last 18 months the company’s revenue has grown more than 4×, reflecting rapid adoption in regulated sectors such as healthcare, financial services, and insurance. Recent milestones include achieving AWS Pattern Partner status and being ranked the #1 company in AI Agent Security & Risk Management by CB Insights. With its new control-plane capabilities, Fiddler plans to deepen integrations across the AI ecosystem and expand its footprint in mission-critical, agent-driven workflows. The latest financing brings total capital raised to $100 million, supporting continued product development and go-to-market expansion.